Lixte Biotechnology Holdings, Inc. (NASDAQ:NMAD – Get Free Report) Director Michael Andrew Holloway purchased 15,000 shares of the business’s stock in a transaction dated Wednesday, November 18th. The shares were acquired at an average cost of $2.82 per share, for a total transaction of $42,300.00. Following the acquisition, the director owned 55,000 shares of the company’s stock, valued at approximately $155,100. The trade was a 37.50% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Lixte Biotechnology Stock Performance
Shares of NASDAQ:NMAD opened at $2.26 on Friday. The stock has a market capitalization of $36.39 million, a price-to-earnings ratio of -1.60 and a beta of 1.37. Lixte Biotechnology Holdings, Inc. has a 1-year low of $2.15 and a 1-year high of $8.38. The company has a 50 day moving average price of $3.67 and a 200 day moving average price of $4.64.
Lixte Biotechnology (NASDAQ:NMAD – Get Free Report) last released its quarterly earnings results on Monday, November 16th. The company reported ($0.74) EPS for the quarter. The firm had revenue of $0.47 million for the quarter.
Institutional Trading of Lixte Biotechnology
Several institutional investors and hedge funds have recently made changes to their positions in NMAD. Legacy Wealth Managment LLC ID bought a new stake in Lixte Biotechnology during the 2nd quarter valued at about $4,457,000. BlackRock Inc. bought a new position in Lixte Biotechnology in the 2nd quarter worth $564,000. Equitable Holdings Inc. purchased a new position in Lixte Biotechnology in the 2nd quarter worth approximately $74,000. Finally, FNY Investment Advisers LLC bought a new stake in Lixte Biotechnology in the 2nd quarter valued at $330,000. Hedge funds and other institutional investors own 5.10% of the company’s stock.
Analyst Ratings Changes
Several equities research analysts have commented on NMAD shares. Weiss Ratings raised shares of Lixte Biotechnology from a “sell (e)” rating to a “sell (d)” rating in a research report on Friday, September 25th. Wall Street Zen lowered shares of Lixte Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, August 22nd. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.
Check Out Our Latest Stock Report on Lixte Biotechnology
Lixte Biotechnology Company Profile
Lixte Biotechnology Holdings is a clinical-stage biotechnology company focused on developing treatments for cancer. Its research centers on compounds that target protein phosphatase 2A (PP2A), an enzyme involved in cellular processes that can influence cancer growth and treatment response. The company’s lead investigational candidate, LB-100, is a small-molecule PP2A inhibitor being studied for potential use alongside existing cancer treatments. Lixte has described its approach as aiming to make tumors more responsive to therapies such as chemotherapy and immunotherapy.
Read More
- Five stocks we like better than Lixte Biotechnology
- Hard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
- 2 Utility Stocks May Offer Relief From AI Volatility, But Rates Are the Real Story
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
Receive News & Ratings for Lixte Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lixte Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
